載入中
NASDAQHealthcareBiotechnology
最新資料
US$20.8014
−US$0.1986 · -0.95%
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
一般交易時段
US$20.8014
−US$0.1986 · -0.95%
盤中時間採用ET。市場資料可能有所延遲。
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
日內區間
目前US$20.8014
52週區間
目前US$20.8014
盤中時間採用ET。市場資料可能有所延遲。
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
日內區間
目前US$20.8014
52週區間
目前US$20.8014
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 1.32億 USD | 1.69億 USD | 7036.1萬 USD | 2625萬 USD | 1630.8萬 USD |
| 銷售、一般及管理費用 | 3859.5萬 USD | 2382.2萬 USD | 1429.6萬 USD | 522.9萬 USD | 241.7萬 USD |
| 營業費用 | 1.71億 USD | 1.92億 USD | 8465.7萬 USD | 3147.9萬 USD | 1872.5萬 USD |
| 利息收入 | 1595.3萬 USD | 1458.8萬 USD | 1275.6萬 USD | 167.6萬 USD | — |
| 利息支出 | — | — | — | 167.6萬 USD | 2.7萬 USD |
| 折舊和攤銷 | 5.9萬 USD | 4.3萬 USD | — | — | — |
| 營業利益 | −1.71億 USD | −1.92億 USD | −8465.7萬 USD | −3147.9萬 USD | −1872.5萬 USD |
| 淨利 | −1.55億 USD | −1.78億 USD | −7189.8萬 USD | −2979.9萬 USD | −1940.8萬 USD |
公司資料更新於 2026年10月14日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI5052.17萬0.00%2.3兆 USD0.03%US$379.89-0.38%
iShares Russell 2000 ETFIWM3488.12萬0.05%777.48億 USD0.19%US$274.29-0.87%
State Street SPDR S&P Biotech ETFXBI3405.14萬0.33%102.75億 USD0.35%US$146.26-0.37%
Vanguard Extended Market ETFVXF1889.43萬0.02%954億 USD0.05%US$230.6-0.83%
iShares Russell 2000 Growth ETFIWO1258.1萬0.09%137.9億 USD0.24%US$347.74-0.96%
iShares Biotechnology ETFIBB1050.68萬0.10%107.38億 USD0.44%US$200.06+0.02%
Vanguard Russell 2000 ETFVTWO847.07萬0.05%180億 USD0.06%US$110.79-0.88%
Schwab U.S. Small-Cap ETFSCHA738.54萬0.03%216.55億 USD0.03%US$32.315-0.75%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
